Daily olive oil intake is feasible to reduce trigeminal neuralgia facial pain: A pilot study.
36-Item Short Form Survey
Demyelination
Diet quality
Extra virgin olive oil
Facial pain
Penn Facial Pain Scale
Trigeminal neuralgia
Journal
Nutrition research (New York, N.Y.)
ISSN: 1879-0739
Titre abrégé: Nutr Res
Pays: United States
ID NLM: 8303331
Informations de publication
Date de publication:
10 Jan 2024
10 Jan 2024
Historique:
received:
02
08
2023
revised:
29
12
2023
accepted:
07
01
2024
medline:
3
2
2024
pubmed:
3
2
2024
entrez:
2
2
2024
Statut:
aheadofprint
Résumé
Extra virgin olive oil (EVOO) is thought to contribute to neuroprotection and, thus, may influence pain symptoms experienced by adults with demyelination-related trigeminal neuralgia (TN). This study aimed to determine the feasibility of daily intake of EVOO and its potential to alleviate facial pain of TN. Adults, self-reporting as female and affected by TN, were enrolled in a 16-week nonblinded, parallel study. After a 4-week baseline, participants were randomized to 60 mL/day EVOO or control (usual diet and no supplemental EVOO) for 12 weeks. Participants completed a daily questionnaire on pain intensity and compliance, the Penn Facial Pain Scale weekly, the 36-Item Short Form Survey monthly, and dietary assessment during baseline and intervention. Participants (n = 52; 53.3 ± 12.9 years) were recruited nationally; 42 completed the study. The EVOO group, with 90% intake compliance, showed significant decreases in the Penn Facial Pain Scale items of interference with general function, interference with orofacial function, and severity of pain from baseline, whereas the control group showed no improvements. EVOO benefit, compared with control, trended for the interference with orofacial function (P = .05). The 36-Item Short Form Survey items of role limitations resulting from emotional problems and role limitations from physical health favored EVOO. The EVOO group significantly improved their Healthy Eating Index 2015 component scores of fatty acids (primarily from increased oleic acid), sodium, and refined grains. EVOO intake of 60 mL/day was feasible for participants experiencing TN and may mitigate pain and improve quality of life. This trial was registered at clinicaltrials.gov (NCT05032573).
Identifiants
pubmed: 38306883
pii: S0271-5317(24)00007-1
doi: 10.1016/j.nutres.2024.01.005
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT05032573']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101-110Informations de copyright
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships and thus declare no conflict of interest.